Silver Book Fact

Cost-effectiveness of flu vaccine

Vaccination for pandemic influenza (pH1N1) prior to an outbreak produces incremental cost-effectiveness ratios for individuals without high risk conditions, ranging from $8,000 to $52,000 per quality-adjusted life year.

Prosser L, Lavelle T, Fiore A, Bridges C, et al. Cost-Effectiveness of 2009 Pandemic Influenza A (H1N1) Vaccination in the United States. PLoS ONE. 2011; 6(7). http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022308

Reference

Title
Cost-Effectiveness of 2009 Pandemic Influenza A (H1N1) Vaccination in the United States
Publication
PLoS ONE
Publication Date
2011
Authors
Prosser L, Lavelle T, Fiore A, Bridges C, et al
Volume & Issue
Volume 6, Issue 7
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Vaccines in development 2013
    Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.  
  • Influenza vaccine use reduces antibiotic use
    Use of LAIV (live attenuated influenza virus) in healthy adults ages 18 to 65 reduced antibiotic use by 43% to 47%.  
  • Life years saved from infectious disease eradication
    Infectious disease eradication in the U.S. led to the following annual life years saved (LYS): 5,811,852 for measles 42,702 for tetanus 212,690 for polio 1,685,740 for smallpox  
  • Cost effectiveness of MMR vaccine
    For every dollar spent on the MMR (measles, mumps, and rubella) vaccine, $21 is saved.  
  • Potential cost effectiveness of shingles vaccines
    The projected cost-effectiveness of a shingles vaccine for adults age 60 and older was estimated at $15,390 – $22,474 from the payer perspective, and $14,450 to $21,524 from the societal…